Articles
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
.avif)
.avif)
How to Develop and Validate NIR-II Probes for In Vivo Imaging ?
From probe chemistry to deep-tissue validation—how NIR-II imaging systems accelerate probe development and translational research.
Why the Choice of Detectors Define Your NIR-II Performance
In NIR-II fluorescence imaging, performance is not defined by wavelength alone. Detectors architecture, pixel geometry, filtering strategy, and modality integration determine whether deep-tissue signal translates into reliable quantitative data.
How NIR-II Is Emerging as a Key Tool in Translational Research
Translational research depends on one principle: preclinical data must predict clinical behavior. Imaging technologies that improve tissue penetration, reduce background interference, and enable quantitative longitudinal assessment are therefore becoming central to drug development and therapeutic validation. NIR-II fluorescence imaging (1000–1700 nm) is increasingly positioned as a strategic modality in this transition from discovery to application.
When to Use NIR-II and When Not To
NIR-II imaging is not simply a longer-wavelength alternative to NIR-I. It enables specific biological questions to be addressed that are difficult, or impossible, to resolve with shorter wavelengths. At the same time, some applications remain better served by bioluminescence. A strategic modality decision begins with the biological endpoint.
